Stock Evaluator: Amylyx Pharmaceuticals, Inc. (AMLX)

Amylyx Pharmaceuticals, Inc. AMLX

$27.52 -0.28 -1.01%
November 17, 2026 4:00:00 PM EST November 10, 2021 Volume: 1,175,395
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Pharmaceuticals

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Commentary & Analysis


Financial Summary

Share Statistics AMLX Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $3,574.0 $433.9 63%
Shares Out (Mil) 118.9 46.5 65%
Institutional Ownership 93.9% 82.2% 63%
Float (Mil) 112.8 47.7 63%
Beta -0.08 0.74 4%
Avg Daily Volume (000s) 1,625 345 76%
Price Change
(52-week)
123.8% 52.0% 97%
Growth AMLX Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 6.4% na
Net Income (5yr) (27.9%) (1.6%) 15%
EPS (5yr) 26.1% 15.1% 77
Dividends (5yr) na 0.0% na
Cash Flow (5yr) (0.9%) (15.1%) 63%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 7 7 8
Current EPS ($0.369) ($1.507) ($1.129)
Month Ago EPS ($0.364) ($1.484) ($1.090)
# Rev Up 0 0 1
# Rev Down 0 1 0
Three Months Ago EPS ($0.359) ($1.481) ($1.138)
Year/Year Chg (3.4%) (1.6%) (55.2%)
Financials AMLX Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) na $289 na
Net Income (TTM) (Mil) ($163) ($11) 8%
EPS (TTM) ($1.448) ($0.600) 17%
Operating Cash Flow (TTM) (Mil) ($130) ($7) 5%
Net Cash Flow (TTM) (Mil) $15 $1 61%
Long-Term Debt (Q1) (Mil) $4 $6 23%
Enterprise Value (Q1) (Mil) $3,029 $331 55%
Valuation AMLX Industry
Median
Percentile
(All Stocks)
P/B 4.74 2.05 80%
P/E na 24.3 na
Dividend Yield na 0.0% na
PEG (5yr hist) na 1.2 na
Ratios AMLX Industry
Median
Percentile
(All Stocks)
Gross Margin na 69.5% na
Net Margin na 3.9% na
ROA (28.4%) (23.3%) 17%
ROE (30.1%) (21.8%) 20%
Liabilities to Assets 4.2% 31.2% 2%
F-Score 4 3 33%

Amylyx Pharmaceuticals, Inc. did not pass any screens on 11/16/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors